14 april 2021
14:49
–
The vaccine manufacturer Pfizer / BioNTech will supply Europe with 50 million extra doses in the second quarter, of which 1.28 million are destined for Belgium. Pfizer / BioNTech will be the European main supplier for the next two years.
–
Pfizer / BioNTech confirms as a reliable supplier of vaccines at a time when both AstraZeneca and Johnson & Johnson are experiencing problems with rare blood clots. Pfizer / BioNTech, which produces in Puurs and Marburg, Germany, will early deliver 50 million vaccines promised for the fourth quarter in the current second quarter. It will deliver 250 million doses of vaccine this quarter instead of 200 million.
–
–
The extra doses will be distributed in proportion to population, EU Commission President Ursula von der Leyen announced in a video address. The announcement is good news for Belgium. It will receive 1.28 million extra injections from Puurs before the end of June.
–
The additional deliveries may partly make up for the temporary postponement of Johnson & Johnson deliveries. The US pharmaceutical giant temporarily halted deliveries on Tuesday after six cases of rare blood clots were discovered in the US. Johnson & Johnson would deliver 55 million doses in the second quarter.
–
Purveyor to the Court
The Commission will negotiate a third contract with Pfizer / BioNTech to supply 1.8 billion doses of modified vaccines over the next two years. ‘We have to learn lessons from the pandemic. We need vaccines that are adapted to the new variants and we need to have them available quickly and in large quantities, ”said von der Leyen.
–
We need vaccines that are adapted to the new variants and we need to have them available quickly and in large quantities.
